Latest news with #EuropeanSocietyofCardiology
Time of India
27-05-2025
- Health
- Time of India
Heart failure patients can benefit from Yoga through THIS way
A recent study presented at Heart Failure 2024 reveals that yoga can significantly improve symptoms in heart failure patients. The research indicates that incorporating yoga, with its focus on breathing and relaxation, alongside medication leads to stronger hearts and increased activity levels. Cardiovascular disease (CVD) is the leading cause of death globally, accounting for more than 17 million lives each year. Alarmingly, 80% of these deaths occur in low and middle-income countries, where access to long-term care and rehabilitation can be limited. Heart failure is one among the many complications of CVD, which significantly impairs the quality of life, leaving patients breathless, fatigued, and often unable to carry out simple daily tasks. A recent study suggests that there may be a powerful, low-cost tool to support these patients: yoga. Yoga and the heart Research presented at Heart Failure 2024, a scientific congress of the European Society of Cardiology (ESC) found that yoga is linked with improvement of symptoms in patients with heart failure. Yoga, which is focused on breathing, meditation, and relaxation, can help heart failure patients build stronger hearts and become more active. 'Patients who practised yoga on top of taking their medications felt better, were able to do more, and had stronger hearts than those who only took drugs for their heart failure. The findings suggest that yoga can be a beneficial complementary therapy in patients with heart failure,' study author Dr. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch vàng CFDs với mức chênh lệch giá thấp nhất IC Markets Đăng ký Undo Ajit Singh of the Indian Council of Medical Research (ICMR), Manipal Academy of Higher Education, India said in a statement. Representative image. Heart failure is a chronic medical condition in which the heart is unable to pump blood effectively enough to meet the body's needs for oxygen and nutrients. In simple words, the heart cannot keep up with its workload, and as a result, the body may not get the oxygen it needs. Over 64 million people are affected by heart failure globally, which leads to devastating impacts on quality of life, with patients feeling tired and breathless, and being unable to participate in their usual activities. Role of yoga in building a stronger heart Though previous studies have shown short-term benefits of yoga in patients with heart failure, this study provides new information about the long-term effects. To understand the long-term effects of yoga, the researchers looked at 85 heart failure patients aged between 30 and 70 from the cardiology outpatient department at Kasturba Hospital in Manipal, India. All of the participants had undergone a heart procedure within the past 6 to 12 months and were already on standard heart failure medications. Patients with severe symptoms were excluded. The average age was 49 years, and 70 (82%) were men. 40 patients were assigned to the yoga group and 45 patients were allocated to the control group, in a non-randomised fashion. All of them followed the guideline-recommended heart failure medications throughout the study. The participants practised yoga under the supervision of experienced faculty in the hospital's Department of Yoga. They demonstrated pranayama (yogic breathwork), meditation, and relaxation techniques to patients in the yoga group. After a week of supervision, the participants were advised to continue it at home once a week for 50 minutes. The progress of the patients was recorded. King Charles' Cancer Secret REVEALED | Royal Whisper EXPOSES Private Health Bombshell | WATCH To evaluate the progress, researchers conducted tests at the beginning of the study, at six months, and at one year. They used echocardiography to measure the heart's pumping ability (left ventricular ejection fraction) and right ventricular function. Blood pressure, heart rate, body weight, and body mass index were also recorded. Functional capacity was measured using the New York Heart Association (NYHA) classification, which assesses a patient's ability to perform everyday tasks, such as walking and climbing stairs. The results were surprising. The participants in the yoga group had significantly greater improvements in all measurements at six months and one year relative to baseline. 'Patients who did yoga had healthier hearts and were more able to carry out ordinary activities such as walking and climbing stairs than those who only took medications. Patients with heart failure should speak to their doctor before starting yoga and should then receive training from an experienced instructor. Prescribed medications should be continued as before. Yoga may be unsuitable for heart failure patients with severe symptoms, who were excluded from our study,' Dr. Singh said. One step to a healthier you—join Times Health+ Yoga and feel the change One step to a healthier you—join Times Health+ Yoga and feel the change
New York Post
21-05-2025
- Health
- New York Post
Quick test is a ‘significant predictor' of a potentially life-threatening condition
What's in your gut might just break your heart — literally. For years, doctors have used body mass index (BMI) as the standard tool for measuring obesity and assessing a patient's risk of developing heart failure. But new research suggests that a simple ratio involving your waistline may be an even better predictor. The best part? You can calculate it yourself at home — here's how. 3 There is no cure for heart disease, but early intervention can slow progression and improve patient outcomes. Studio Romantic – Gut check Research presented this week at the European Society of Cardiology's scientific congress looked at 1,792 adults aged 45 to 73. Participants were split into three groups: those with normal blood sugar, prediabetes and diabetes. Over a 13-year follow-up period, 132 developed heart failure. Here's the kicker: researchers linked a larger waist relative to height to a 'significantly increased' risk of heart failure. In fact, those with a waist-to-height ratio (WtHR) of 0.65 or higher were nearly three times more likely to develop the potentially deadly condition. 'BMI is the most common measure of obesity, but it is influenced by factors such as sex and ethnicity, and does not take into account the distribution of body fat,' said study co-author Dr. John Molvin of Lund University in Sweden. 3 The circumference of your waist should be less than half your height. íÅ¡í¸íâ¬í¸í»í» í íâ¹í¶í¾í² – Unlike BMI, WtHR targets central adiposity, or excess fat in the abdomen that surrounds internal organs. This fat poses a stronger risk for health problems such as heart disease, Type 2 diabetes and even an early death compared to general obesity. 'We found that WtHR was a significant predictor of incident [heart failure],' said Molvin, adding that it may be a more reliable measure than BMI to identify those at risk and who could benefit from obesity treatments. Next, the researchers plan to explore whether WtHR can predict other health issues, like Type 2 diabetes and high blood pressure. Killing millions, costing billions Heart failure is a progressive condition that occurs when the heart muscle is damaged and can no longer pump enough blood and oxygen to the body's other organs. It's extremely common in the US, with rates climbing steadily over the last decade, particularly in younger populations. 3 Heart disease is a major public health concern and a growing economic burden in the US. Nadzeya – Some 6.7 million Americans over 20 are living with heart failure. That number is expected to jump to 8.7 million by 2030 and a staggering 11.4 million by 2050, according to the Heart Failure Society of America. Key risk factors include an age over 65, a family history and high blood pressure or coronary artery disease. Obesity also plays a major role, with studies linking it to 11% of heart failure cases in men and 14% in women. While there's no cure for heart failure, early detection is critical. Timely treatment can slow progression, improve quality of life and prevent complications. Without it, heart disease can be fatal. It's a top killer in the US, responsible for 8.5% of cardiovascular-related deaths. How to calculate your waist-to-height ratio To calculate your WtHR, all you need is a tape measure (and maybe a calculator). Simply measure the circumference of your waist and divide it by your height. Experts say your waist should be less than half your height, with a healthy WtHR falling between 0.4 and 0.49. 'Having a waist measurement that is less than half your height is ideal,' Molvin said. For example, if you're 170 centimeters tall, your waist should ideally be under 85 centimeters.
Business Wire
19-05-2025
- Business
- Business Wire
Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present the latest data from its flagship transthyretin amyloidosis (TTR) franchise at the upcoming Heart Failure 2025 Congress, a scientific congress of the European Society of Cardiology, taking place May 17-20 in Belgrade, Serbia. The latest analyses of the HELIOS-B Phase 3 study of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM), including further outcomes data on cardiovascular hospitalizations and urgent heart failure visits up to 42-months, will be presented as a late-breaking abstract in the 'Hottest Trials and Trial Updates 1' session. Data from the HELIOS-B study supported the recent approvals of AMVUTTRA ® (vutrisiran) for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults in the U.S. and Brazil. These data also supported the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of vutrisiran for the same indication. AMVUTTRA is an RNAi therapeutic that works upstream to deliver rapid knockdown of transthyretin, addressing the disease at its source, with four subcutaneous doses per year. Additional updates to be presented include the design and rationale of the TRITON-CM Phase 3 study of nucresiran (ALN-TTRsc04), an investigational next-generation TTR silencer, in patients with ATTR-CM, as well as an additional analysis from the HELIOS-B study of vutrisiran in patients with ATTR-CM who experienced disease progression while being treated with tafamidis. Presentation Details Vutrisiran Reduces All-Cause Mortality, Cardiovascular Mortality, and Cardiovascular Events in Patients with Transthyretin Amyloid Cardiomyopathy: Analysis from the HELIOS-B Trial Session: Hottest Trials and Trial Updates 1 Saturday, May 17, 11:50 – 11:58 CEST, 5:50 – 5:58 A.M. EST Presenting Author: Marianna Fontana, United Kingdom Clinical Presentation and Treatment Landscape of Patients with Transthyretin Amyloidosis With Cardiomyopathy: A Real-world Study in Five European Countries and Japan Session: Novel Insights into Heart Failure Therapeutics Sunday, May 18, 13:00 – 13:45 CEST, 7:00 – 7:45 A.M. EST Presenter: Caroline Morbach, Germany Utility of Genetic Testing For Diagnosing hATTR Patients: Results from a European and Middle East Genetic Testing Program Session: Novel Insights into Heart Failure Therapeutics Monday, May 19, 9:00 – 10:00 CEST, 3:00 – 4:00 A.M. EST Presenter: Antoine Bondue, Belgium Design and Rationale of a Phase 3 Study to Evaluate Efficacy and Safety of Nucresiran (ALN-TTRsc04) in Patients with Transthyretin Amyloidosis with Cardiomyopathy Session: Research Methodology Monday, May 19, 14:00 – 15:00 CEST, 8:00 – 9:00 A.M. EST Presenter: Marianna Fontana, United Kingdom Vutrisiran In Patients With Transthyretin Amyloidosis with Cardiomyopathy In HELIOS-B Who Had Progressed On Tafamidis Session: Evolving Treatment Paradigms in Heart Failure: SGLT2 Inhibition to TTR Stabilisation and Beyond Tuesday, May 20, 9:21 – 9:30 CEST, 3:21 – 3:30 A.M. EST Presenter: Jose Gonzalez-Costello, Spain About AMVUTTRA ® (vutrisiran) AMVUTTRA ® (vutrisiran) is an RNAi therapeutic that delivers rapid knockdown of variant and wild-type transthyretin (TTR), addressing the underlying cause of transthyretin (ATTR) amyloidosis. Administered quarterly via subcutaneous injection, vutrisiran is approved and marketed in more than 15 countries for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. In Europe, it is administered as a subcutaneous injection once every three months, either by a healthcare professional, or self-administered by patients or their caregivers. Vutrisiran is also in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), which encompasses both wild-type and hereditary forms of the disease. About ATTR Transthyretin amyloidosis (ATTR) is an underdiagnosed, rapidly progressive, debilitating and fatal disease caused by misfolded transthyretin (TTR) proteins, which accumulate as amyloid deposits in various parts of the body, including the nerves, heart and gastrointestinal tract. Patients may present with polyneuropathy, cardiomyopathy, or both manifestations of disease. There are two different forms of ATTR – hereditary ATTR (hATTR), which is caused by a TTR gene variant and affects approximately 50,000 people worldwide, and wild-type ATTR (wtATTR), which occurs without a TTR gene variant and impacts an estimated 200,000 – 300,000 people worldwide. 1-4 About RNAi RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as 'a major scientific breakthrough that happens once every decade or so,' and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today's medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases. About Alnylam Pharmaceuticals Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its ' Alnylam P 5 x25 ' strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. 1 Hawkins PN, Ando Y, Dispenzeri A, et al. Ann Med. 2015;47(8):625-638. 2 Gertz MA. Am J Manag Care. 2017;23(7):S107-S112. 3 Conceicao I, Gonzalez-Duarte A, Obici L, et al. J Peripher Nerv Syst 4 Ando Y, Coelho T, Berk JL, et al. Orphanet J Rare Dis. 2013;8:31.
Hindustan Times
19-05-2025
- Health
- Hindustan Times
Your waist size matters. Study says, it can predict heart failure
For years, the risk of heart failure has been primarily linked to obesity and Body Mass Index (BMI). However, a new study presented at Heart Failure 2025 suggests that waist-to-height ratio may be a more accurate indicator. Researchers from Lund University in Sweden found that fat distribution—specifically around the waist—has a greater impact on heart health than overall body weight, highlighting the need to shift focus from BMI to body fat placement. Also read | Cardiac surgeon reveals why controlling high blood pressure is the 1st step to preventing heart failure The findings were presented at the European Society of Cardiology's scientific congress in Belgrade, Serbia on May 18. Dr. Amra Jujic from Lund University, who presented the study said, 'BMI is the most common measure of obesity, but it is influenced by factors such as sex and ethnicity and does not take into account the distribution of body fat. Waist-to-height ratio is considered a more robust measure of central adiposity, the harmful deposition of fat around visceral organs.' The study was conducted on 1,792 participants from the Malmö Preventive Project for a median of 12.6 years, within the age range of 45 to 73 years. Individuals were selected on the basis of equal thirds having normal blood glucose levels, impaired fasting glucose, or diabetes. During the course of the study, 132 participants developed heart failure. When probed, it was observed that the waist-to-height ratio had a significant impact on heart health risk. Also read | Cardiologist shares 10 things he does every day to lower heart disease risk: 10,000 steps to start the day with protein Explaining what an ideal waistline should be for optimal heart health, study co-author Dr. John Molvin from Lund University and Malmö University Hospital said, 'Having a waist measurement that is less than half your height is ideal.' The researchers concluded that measuring waist circumference during routine blood pressure checkups should become standard practice, as it provides valuable insight into body fat distribution. They emphasized that where fat is stored in the body plays a crucial role in heart health—often more so than total body weight. These findings could potentially revolutionize the approach to obesity treatment, shifting the focus from weight alone to fat location and its health impact. Also read | Waist size in men could better predict risk of cancer than BMI, finds study: 'Extra 4 inches increased cancer risk by…' Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
Business Insider
18-05-2025
- Health
- Business Insider
Cytokinetics presents additional data related to Aficamten
Cytokinetics (CYTK) announced that additional data arising from two analyses from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy, and results from a real-world analysis related to non-obstructive HCM were presented at the European Society of Cardiology Heart Failure 2025 Congress. The results from an analysis of the efficacy of aficamten in patients with obstructive HCM and mild symptoms in SEQUOIA-HCM were also simultaneously published in The European Heart Journal. Effect of Aficamten in Patients with Mild Symptoms and Moderate-to-Severe Symptoms : At the end of the treatment period, 54% of patients with mild symptoms and 36% of patients with moderate-to-severe symptoms were asymptomatic. Additionally, more than half of patients in both groups had an improvement of at least one NYHA Functional Class. Improvements in resting and Valsalva left ventricular outflow tract gradients and NT-proBNP also did not differ significantly between the two groups. The safety and tolerability profile of aficamten was similar to placebo in both subgroups. These data indicate that, in SEQUOIA-HCM, the effect of aficamten was observed independent of baseline symptom burden in patients with obstructive HCM. Effect of Aficamten in Patients with Obstructive HCM Consistent Across Geographic Regions: The effect of aficamten on the primary endpoint of change in pVO2 and all secondary endpoints was consistent, with no significant differences across regions.
